1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Biologics
1.2.3 Small Molecule Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Lung Adenocarcinoma
1.3.3 Squamous Cell Lung Carcinoma
1.3.4 Large-cell Lung Carcinoma
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-small Cell Lung Cancer Drugs Market Perspective (2017-2028)
2.2 Non-small Cell Lung Cancer Drugs Growth Trends by Region
2.2.1 Non-small Cell Lung Cancer Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Non-small Cell Lung Cancer Drugs Historic Market Size by Region (2017-2022)
2.2.3 Non-small Cell Lung Cancer Drugs Forecasted Market Size by Region (2023-2028)
2.3 Non-small Cell Lung Cancer Drugs Market Dynamics
2.3.1 Non-small Cell Lung Cancer Drugs Industry Trends
2.3.2 Non-small Cell Lung Cancer Drugs Market Drivers
2.3.3 Non-small Cell Lung Cancer Drugs Market Challenges
2.3.4 Non-small Cell Lung Cancer Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-small Cell Lung Cancer Drugs Players by Revenue
3.1.1 Global Top Non-small Cell Lung Cancer Drugs Players by Revenue (2017-2022)
3.1.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Non-small Cell Lung Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-small Cell Lung Cancer Drugs Revenue
3.4 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio
3.4.1 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Drugs Revenue in 2021
3.5 Non-small Cell Lung Cancer Drugs Key Players Head office and Area Served
3.6 Key Players Non-small Cell Lung Cancer Drugs Product Solution and Service
3.7 Date of Enter into Non-small Cell Lung Cancer Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-small Cell Lung Cancer Drugs Breakdown Data by Type
4.1 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Type (2017-2022)
4.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Type (2023-2028)
5 Non-small Cell Lung Cancer Drugs Breakdown Data by Application
5.1 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Application (2017-2022)
5.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Non-small Cell Lung Cancer Drugs Market Size (2017-2028)
6.2 North America Non-small Cell Lung Cancer Drugs Market Size by Type
6.2.1 North America Non-small Cell Lung Cancer Drugs Market Size by Type (2017-2022)
6.2.2 North America Non-small Cell Lung Cancer Drugs Market Size by Type (2023-2028)
6.2.3 North America Non-small Cell Lung Cancer Drugs Market Share by Type (2017-2028)
6.3 North America Non-small Cell Lung Cancer Drugs Market Size by Application
6.3.1 North America Non-small Cell Lung Cancer Drugs Market Size by Application (2017-2022)
6.3.2 North America Non-small Cell Lung Cancer Drugs Market Size by Application (2023-2028)
6.3.3 North America Non-small Cell Lung Cancer Drugs Market Share by Application (2017-2028)
6.4 North America Non-small Cell Lung Cancer Drugs Market Size by Country
6.4.1 North America Non-small Cell Lung Cancer Drugs Market Size by Country (2017-2022)
6.4.2 North America Non-small Cell Lung Cancer Drugs Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Non-small Cell Lung Cancer Drugs Market Size (2017-2028)
7.2 Europe Non-small Cell Lung Cancer Drugs Market Size by Type
7.2.1 Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2017-2022)
7.2.2 Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2023-2028)
7.2.3 Europe Non-small Cell Lung Cancer Drugs Market Share by Type (2017-2028)
7.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Application
7.3.1 Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2017-2022)
7.3.2 Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2023-2028)
7.3.3 Europe Non-small Cell Lung Cancer Drugs Market Share by Application (2017-2028)
7.4 Europe Non-small Cell Lung Cancer Drugs Market Size by Country
7.4.1 Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2017-2022)
7.4.2 Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size (2017-2028)
8.2 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Type
8.2.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Application
8.3.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region
8.4.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non-small Cell Lung Cancer Drugs Market Size (2017-2028)
9.2 Latin America Non-small Cell Lung Cancer Drugs Market Size by Type
9.2.1 Latin America Non-small Cell Lung Cancer Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Non-small Cell Lung Cancer Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Non-small Cell Lung Cancer Drugs Market Share by Type (2017-2028)
9.3 Latin America Non-small Cell Lung Cancer Drugs Market Size by Application
9.3.1 Latin America Non-small Cell Lung Cancer Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Non-small Cell Lung Cancer Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Non-small Cell Lung Cancer Drugs Market Share by Application (2017-2028)
9.4 Latin America Non-small Cell Lung Cancer Drugs Market Size by Country
9.4.1 Latin America Non-small Cell Lung Cancer Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Non-small Cell Lung Cancer Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size (2017-2028)
10.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Type
10.2.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Application
10.3.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country
10.4.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Introduction
11.1.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Drugs Business (2017-2022)
11.1.5 AstraZeneca Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Details
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Non-small Cell Lung Cancer Drugs Business (2017-2022)
11.2.5 Bristol-Myers Squibb Company Recent Developments
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Details
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Introduction
11.3.4 Eli Lilly and Company Revenue in Non-small Cell Lung Cancer Drugs Business (2017-2022)
11.3.5 Eli Lilly and Company Recent Developments
11.4 F. Hoffmann-La Roche Ltd
11.4.1 F. Hoffmann-La Roche Ltd Company Details
11.4.2 F. Hoffmann-La Roche Ltd Business Overview
11.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Introduction
11.4.4 F. Hoffmann-La Roche Ltd Revenue in Non-small Cell Lung Cancer Drugs Business (2017-2022)
11.4.5 F. Hoffmann-La Roche Ltd Recent Developments
11.5 Merck & Co., Inc.
11.5.1 Merck & Co., Inc. Company Details
11.5.2 Merck & Co., Inc. Business Overview
11.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Introduction
11.5.4 Merck & Co., Inc. Revenue in Non-small Cell Lung Cancer Drugs Business (2017-2022)
11.5.5 Merck & Co., Inc. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
